Reviewed by a board-certified obesity medicine physician. Last updated March 2026.

The Affordability Problem

Cost is the single largest barrier to GLP-1 treatment in the United States. According to KFF polling, 56% of current and former GLP-1 users report difficulty affording their medication [1]. List prices for branded GLP-1 injectables range from $935 to $1,650 per month, placing them out of reach for many patients without insurance coverage or manufacturer assistance.

The gap between list price and actual patient cost is enormous, and navigating the options requires understanding several distinct pricing channels.

2026 Pricing by Medication

Semaglutide (Wegovy)

List price: $1,349 to $1,650/month for the injectable pen.

NovoCare cash-pay program: $499/month for eligible self-pay patients, purchased directly through Novo Nordisk's patient services program [2].

Oral Wegovy tablet: $149 to $299/month at select pharmacies. The oral formulation, approved by the FDA in December 2025, carries a substantially lower price point and eliminates the need for injections.

Manufacturer savings card: Commercially insured patients may pay as little as $0 to $25/month. The savings card covers the difference between insurance copay and these amounts. Not available for Medicare, Medicaid, or Tricare beneficiaries.

Tirzepatide (Zepbound)

List price: $1,059 to $1,177/month.

LillyDirect vials: $299 to $449/month depending on dose, available through Eli Lilly's direct-to-consumer pharmacy program [3]. These are single-dose vials (not pens) that require a syringe for injection. The lower cost makes tirzepatide accessible to self-pay patients for the first time.

Manufacturer savings card: Commercially insured patients may pay as little as $25/month.

Liraglutide (Saxenda)

List price: $1,349 to $1,430/month. No significant manufacturer discount programs remain active. Saxenda is less commonly prescribed given the superior efficacy of semaglutide and tirzepatide.

Insurance Coverage Landscape

Commercial Insurance

Coverage has expanded significantly since 2023, but remains inconsistent. Most large employer-sponsored plans now cover at least one GLP-1 for weight management, though prior authorization is nearly universal. Common requirements include documented BMI, evidence of prior diet/exercise attempts, and sometimes a trial of an older medication first (step therapy).

When insurance covers the medication, out-of-pocket costs with a manufacturer savings card typically fall between $0 and $50/month.

Medicare

Medicare Part D does not cover anti-obesity medications, including Wegovy and Zepbound. The Treat and Reduce Obesity Act has been introduced in Congress multiple times but has not passed as of March 2026. Part D does cover Ozempic and Mounjaro when prescribed for type 2 diabetes [4].

Some Medicare Advantage plans offer supplemental weight management benefits that may partially cover GLP-1 costs. Check your specific plan documents.

Medicaid

Only 13 states currently provide Medicaid coverage for GLP-1 medications prescribed for obesity [5]. Those states are: California, Colorado, Connecticut, Delaware, Illinois, Maryland, Massachusetts, Minnesota, New York, Oregon, Pennsylvania, Vermont, and Washington. Coverage in remaining states is limited to diabetes indications.

Coverage by Major Carrier

Policies vary by plan tier and employer, but general trends as of 2026:

  • UnitedHealthcare: Covers Wegovy and Zepbound on most commercial plans. Prior authorization required.
  • Blue Cross Blue Shield: Varies significantly by state affiliate. Many cover Wegovy; Zepbound coverage is expanding.
  • Cigna: Covers both Wegovy and Zepbound on most commercial plans.
  • Aetna: Covers Wegovy on most plans. Zepbound coverage varies.
  • Kaiser Permanente: Covers GLP-1 medications through internal prescribing protocols.

Compounded GLP-1 Medications

Compounded semaglutide is available from some pharmacies at $200 to $500/month. Compounded tirzepatide ranges from $300 to $600/month. These are not FDA-approved products and are manufactured by compounding pharmacies under different regulatory oversight than branded medications.

If you consider compounded options, verify that the pharmacy is a 503B-registered outsourcing facility, which operates under FDA inspection and must follow current Good Manufacturing Practice standards. The FDA's position on compounded GLP-1 medications has evolved; check fda.gov for the most current guidance [6].

Strategies to Reduce Costs

  1. Start with manufacturer savings cards. These provide the largest discounts for commercially insured patients and can be applied at any retail pharmacy.
  2. Ask about LillyDirect or NovoCare programs. Self-pay pricing through manufacturer channels is substantially lower than retail pharmacy pricing.
  3. Consider oral Wegovy. At $149 to $299/month, the tablet formulation is the lowest-cost branded GLP-1 option.
  4. Appeal insurance denials. Prior authorization denials are frequently overturned with a letter from your provider documenting medical necessity. Ask your clinic for help with the appeal process.
  5. Use HSA or FSA funds. Prescription GLP-1 medications are eligible Health Savings Account and Flexible Spending Account expenses.
  6. Apply for Patient Assistance Programs. Both Novo Nordisk and Eli Lilly offer free medication to qualifying uninsured patients below certain income thresholds.

Use our clinic directory to find providers who offer transparent pricing and can help you navigate insurance coverage and savings programs.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication.

Sources

  1. KFF Health Tracking Poll, May 2024. "Public Opinion on GLP-1 Drugs for Weight Loss." https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/
  2. Novo Nordisk. NovoCare Patient Savings. https://www.novocare.com/wegovy/savings-card.html
  3. Eli Lilly. LillyDirect Pharmacy Services. https://www.lilly.com/lillydirect/
  4. CMS. Medicare Part D Drug Coverage. https://www.cms.gov/medicare/coverage/prescription-drug-coverage
  5. KFF. Medicaid Coverage of and Spending on GLP-1s. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
  6. FDA. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  7. CDC. Adult Obesity Prevalence Maps. https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html